摘要
目的探讨烯丙雌醇联合利托君治疗高龄初产妇先兆早产患者的临床效果。方法选择2021年6月至2023年6月四会市人民医院收治的82例确诊为先兆早产的高龄初产妇为研究对象,应用随机数字表法将其分为对照组和观察组,各41例。对照组应用利托君保胎治疗,观察组应用烯丙雌醇+利托君保胎治疗,比较两组治疗总有效率及保胎成功率、药物不良反应发生情况等。结果观察组的治疗总有效率(95.12%)较对照组(80.49%)高(P<0.05);观察组保胎成功率高于对照组,分娩孕龄大于对照组(P<0.05);两组围生儿不良结局发生率、药物不良反应发生率比较,差异无统计学意义(P>0.05)。结论烯丙雌醇与利托君联合治疗能够改善先兆早产高龄产妇的妊娠结局,值得推广应用。
Objective To explore the clinical effect of Allylestradiol combined with Ritodrine in the treatment of elderly primipara with threatened prem ature birth.Methods A total of 82 elderly prim iparas diagnosed with threatened premature birth in Sihui People’s Hospital from June 2021 to June 2023 were selected as the research objects.They were divided into control group and observation group by random number table method,with 41 cases in each group.The control group was treated with Ritodrine,and the observation group was treated with Allylestradiol+Ritodrine.The total effective rate of treatment,the success rate of fetal protection,and the occurrence of adverse drug reactions were compared between the two groups.Results The total effective rate of the observation group(95.12%)was higher than that of the control group(80.49%)(P<0.05).The success rate of fetal protection in the observation group was higher than that in the control group,and the gestational age of delivery was greater than that in the control group(P<0.05).There was no significant difference in the incidence of perinatal adverse outcomes and adverse drug reactions between the two groups(P>0.05).Conclusion The combination treatment of Allylestradiol and Ritodrine can improve the pregnancy outcome of elderly primipara with threatened premature birth,which is worth popularization and application.
作者
梁小庄
杨弋
黄丽芳
LIANG Xiaozhuang;YANG Yi;HUANG Lifang(Department of Obstetrics and Gynecology,Sihui People’s Hospital,Guangdong Province,Sihui 526200,China)
出处
《妇儿健康导刊》
2024年第14期68-72,共5页
JOURNAL OF WOMEN AND CHILDREN'S HEALTH GUIDE
关键词
先兆早产
高龄初产妇
烯丙雌醇
利托君
妊娠结局
Threatened premature birth
Elderly primipara
Allylestradiol
Ritodrine
Pregnancy outcome